Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int J Cancer ; 47(2): 281-4, 1991 Jan 21.
Artigo em Inglês | MEDLINE | ID: mdl-1988371

RESUMO

Conjugates of 1-beta-D-arabinofuranosylcytosine (araC) with two polysaccharides such as polygalacturonic acid (PGA) and carboxymethylated yeast beta-D-glucan (CMG) were tested for their antileukemic activity in vitro on a L1210 cell line in suspension culture, in soft agar assay and in vivo on L1210, L1210/araC- and P388-leukemia-bearing mice. Both conjugates showed high activity in vitro in soft agar assay, compared with araC. Single administration of PGA-araC or CMG-araC increased the survival time 1.5 x or 1.7 x, respectively, compared with araC in vivo in L1210-leukemia-bearing mice. The conjugates were not active against araC-resistant leukemia line L1210/araC. The marked effect of both PGA-araC and CMG-araC against leukemia L1210 and P388 is probably due to the prolonged release of free araC from conjugates caused by hydrolysis.


Assuntos
Citarabina/análogos & derivados , Glucanos/uso terapêutico , Leucemia L1210/tratamento farmacológico , Leucemia P388/tratamento farmacológico , Pectinas/uso terapêutico , beta-Glucanas , Animais , Citarabina/uso terapêutico , DNA/biossíntese , Feminino , Leucemia L1210/metabolismo , Leucemia P388/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos DBA
2.
Neoplasma ; 31(6): 641-7, 1984.
Artigo em Inglês | MEDLINE | ID: mdl-6395026

RESUMO

The following platinum complexes have been tested: cis-DDP--cis-diamminedichloroplatinum(II), Platinex--1,2-diaminocyclohexaneplatinum(II)citrate, Platuran--1,2-diaminocyclohexaneplatinum(II)-glucarate , TMA--1,2-diaminocyclohexaneplatinum(II)-4-carboxyphthalate,o xo-PT--cis-diamminedichloro-trans-dihydroxyplatinum(IV), CHIP--cis-dichloro-bis-(isopropylamine)-trans-dihydroxyplatinum(IV ), CBDCA--cis-diammine-cyclobutane-1,1-dicarboxylatoplatinum(II ). The activity of all tested complexes againt L1210 cells was higher in soft agar colony assay when compared with suspension culture of the same target cells. Using various doses and schedules oxo-Pt, CBDCA and cis-DDP exhibited the highest in vivo activity against P388 leukemia.


Assuntos
Antineoplásicos/uso terapêutico , Leucemia L1210/tratamento farmacológico , Leucemia P388/tratamento farmacológico , Leucemia Experimental/tratamento farmacológico , Compostos Organoplatínicos/uso terapêutico , Platina , Animais , Carboplatina , Linhagem Celular , Cisplatino/análogos & derivados , Cisplatino/uso terapêutico , Avaliação Pré-Clínica de Medicamentos , Feminino , Injeções Intraperitoneais , Masculino , Camundongos , Camundongos Endogâmicos DBA
3.
Neoplasma ; 31(6): 649-53, 1984.
Artigo em Inglês | MEDLINE | ID: mdl-6542968

RESUMO

In vitro drug resistance was induced against cis-diamminedichloroplatinum(II) (cis-DDP), 1,2-diaminocyclohexaneplatinum-(II)citrate (PEX) and 1,2-diaminocyclohexaneplatinum(II)glucarate (PTU) in L1210 leukemia cell line. Using the resistant sublines cross-resistance was found between cis-DDP and cis-diamminecyclobutane-1,1-dicarboxylatoplatinum(II) (CBDCA) and between the three 1,2-diaminocyclohexane (DACH) derivatives tested. No (or low degree) cross-resistance was found between cis-DDP and DACH derivatives.


Assuntos
Antineoplásicos/uso terapêutico , Leucemia L1210/tratamento farmacológico , Compostos Organoplatínicos/uso terapêutico , Platina , Animais , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Cisplatino/uso terapêutico , Avaliação Pré-Clínica de Medicamentos , Resistência a Medicamentos , Leucemia L1210/genética , Camundongos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA